- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
- Immunocore presented two posters at CROI 2024
- Immunocore to present at upcoming investor conferences
- Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
- Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
- Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
- Immunocore Prices Upsized Convertible Senior Notes Offering
- Immunocore Announces Proposed Convertible Senior Notes Offering
More ▼
Key statistics
On Friday, Immunocore Holdings PLC (IMCR:NSQ) closed at 58.46, 38.50% above the 52 week low of 42.21 set on Oct 30, 2023.
52-week range
Open | 57.75 |
---|---|
High | 58.94 |
Low | 56.10 |
Bid | 23.18 |
Offer | 92.70 |
Previous close | 58.00 |
Average volume | 473.13k |
---|---|
Shares outstanding | 48.76m |
Free float | 44.13m |
P/E (TTM) | -- |
Market cap | 2.83bn USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼